Singh Sukhwinder, Capoor Malini Rajinder, Varshney Swati, Gupta Dipendra Kumar, Verma Pradeep Kumar, Ramesh V
Department of Microbiology, VMMC and Safdarjung Hospital, New Delhi, India.
Department of ICU, VMMC and Safdarjung Hospital, New Delhi, India.
Indian J Med Microbiol. 2019 Oct-Dec;37(4):536-541. doi: 10.4103/ijmm.IJMM_19_146.
Over the past four decades, there has been an increase in the number of fatal opportunistic invasive trichosporonosis cases especially in immunocompromised hosts.
The objective of the study is to evaluate the epidemiological, clinical details and antifungal susceptibility pattern of the patients with Trichosporon infections.
Twenty-four clinical isolates of Trichosporon species isolated from blood, samples, pleural fluid and nail were included in this study, over a period of 12 years (2005-2016) in a tertiary hospital in North India. The isolates were characterised phenotypically and few representative isolates were sequenced also. The minimum inhibitory concentration (MIC) was determined as per Clinical and Laboratory Standards Institute, 2012.
Trichosporon spp. from blood culture (57.78%), nail (37.5%) and pleural fluid (4.17%). On phenotypic tests, 79.16% of the isolates were Trichosporon asahii, followed by Trichosporon dermatis (8.33%), Trichosporon japonicum (4.17%), Trichosporon ovoides (4.17%) and Trichosporon mucoides (4.17%). The MIC range of Trichosporon species from invasive infections were fluconazole (0.06-256 μg/ml), amphotericin B (0.125-16 μg/ml), voriconazole (0.0616-8 μg/ml), posaconazole (0.0616-32 μg/ml) and caspofungin (8-32 μg/ml). The isolates from superficial infection were resistant to fluconazole (0.06-256 μg/ml) and itraconazole (0.125-32 μg/ml), all were susceptible to ketoconazole and while only two were resistant to voriconazole (0.25-4 μg/ml).
T. asahii was the most common isolate. Disseminated trichosporonosis is being increasingly reported worldwide including India and represents a challenge for both diagnosis and species identification. Prognosis is limited, and antifungal regimens containing triazoles appear to be the best therapeutic approach. In addition, accurate identification, removal of central venous lines and voriconazole-based treatment along with control of underlying conditions were associated with favourable outcomes.
在过去的四十年中,致命的机会性侵袭性毛孢子菌病病例数量有所增加,尤其是在免疫功能低下的宿主中。
本研究的目的是评估毛孢子菌感染患者的流行病学、临床细节和抗真菌药敏模式。
在印度北部一家三级医院,于12年期间(2005 - 2016年)从血液、样本、胸水和指甲中分离出的24株毛孢子菌临床分离株纳入本研究。对分离株进行表型鉴定,少数代表性分离株也进行了测序。根据临床和实验室标准协会2012年的标准测定最低抑菌浓度(MIC)。
毛孢子菌属分离株来自血培养(57.78%)、指甲(37.5%)和胸水(4.17%)。表型试验中,79.16%的分离株为阿萨希毛孢子菌,其次是皮肤毛孢子菌(8.33%)、日本毛孢子菌(4.17%)、卵形毛孢子菌(4.17%)和黏液毛孢子菌(4.17%)。侵袭性感染的毛孢子菌属的MIC范围为氟康唑(0.06 - 256μg/ml)、两性霉素B(0.125 - 16μg/ml)、伏立康唑(0.0616 - 8μg/ml)、泊沙康唑(0.0616 - 32μg/ml)和卡泊芬净(8 - 32μg/ml)。浅表感染的分离株对氟康唑(0.06 - 256μg/ml)和伊曲康唑(0.125 - 32μg/ml)耐药,所有分离株对酮康唑敏感,而只有两株对伏立康唑(0.25 - 4μg/ml)耐药。
阿萨希毛孢子菌是最常见的分离株。包括印度在内,全球范围内播散性毛孢子菌病的报道日益增多,这对诊断和菌种鉴定都构成了挑战。预后有限,含三唑类的抗真菌治疗方案似乎是最佳治疗方法。此外,准确鉴定、拔除中心静脉导管、基于伏立康唑的治疗以及控制基础疾病与良好预后相关。